MANE

+ Watchlist + Portfolio

Veradermics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $117.22
52-Week Range: $32.00 – $131.24
Market Cap: $4.88B
P/E (TTM): —
EPS (TTM): -2.50
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.00
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 70.53
Debt/Equity: 0.00
Total Debt: $428.00K
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.06B

MANE Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$14.97M	$23.28M	$62.06M
Selling, General & Admin	$2.35M	$3.50M	$10.28M
Operating Expenses	$17.32M	$26.38M	$71.56M
Operating Income	-$17.32M	-$26.38M	-$71.56M
EBITDA	-$16.45M	-$25.90M	-$70.00M
Pretax Income	-$16.49M	-$26.49M	-$70.00M
Income Tax	$0.00	$0.00	$0.00
Net Income	-$16.49M	-$26.49M	-$70.00M
Diluted EPS	-1.51	-1.37	-2.38
Diluted Shares	13.80M	19.91M	35.08M

MANE Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	$16.30M	$53.08M	$21.77M
Receivables	$0.00	$1.38M	$1.25M
Current Assets	$17.56M	$55.53M	$152.49M
Total Assets	$17.56M	$55.53M	$152.62M
Current Liabilities	$3.05M	$4.72M	$9.15M
Long-Term Debt	$786.00K	—	—
Total Debt	$786.00K	$0.00	$4.00K
Total Liabilities	$39.80M	$104.02M	$273.63M
Retained Earnings	-$22.74M	-$49.23M	-$123.42M
Shareholders' Equity	-$22.24M	-$48.48M	-$121.01M
Working Capital	$14.51M	$50.82M	$143.34M

MANE Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.51M	-$23.69M	-$71.60M
Capital Expenditure	—	—	-$24.00K
Free Cash Flow	-$13.51M	-$23.69M	-$71.63M
Stock-Based Compensation	$206.00K	$250.00K	$1.44M
Investing Cash Flow	—	$0.00	-$118.86M
Financing Cash Flow	$13.89M	$60.48M	$159.14M
Net Change in Cash	$385.00K	$36.79M	-$31.32M

MANE Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.95M	$11.45M	$14.33M	$18.10M	$18.19M	$20.93M	$18.61M
Selling, General & Admin	$1.02M	$1.47M	$1.74M	$2.25M	$4.82M	$8.94M	$10.95M
Operating Expenses	$5.58M	$12.88M	$16.07M	$19.82M	$22.75M	$29.71M	$29.55M
Operating Income	-$5.58M	-$12.88M	-$16.07M	-$19.82M	-$22.75M	-$29.71M	-$29.55M
EBITDA	-$5.37M	-$12.88M	-$16.07M	-$19.16M	-$21.85M	-$29.71M	-$29.55M
Pretax Income	-$5.66M	-$12.40M	-$15.64M	-$20.10M	-$21.85M	-$27.23M	-$23.50M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$5.66M	-$12.40M	-$15.64M	-$20.10M	-$21.85M	-$27.23M	-$23.50M
Diluted EPS	—	-0.73	-0.51	—	-0.62	-1.32	-0.58
Diluted Shares	—	19.91M	35.08M	—	35.08M	22.70M	40.44M

MANE Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$53.08M	$5.66M	$53.08M	$5.66M	$21.77M	$168.41M	$319.33M
Receivables	$1.38M	$1.23M	$1.38M	$1.23M	$1.25M	$1.65M	$1.59M
Current Assets	$55.53M	$18.71M	$55.53M	$18.71M	$152.49M	$397.07M	$824.75M
Total Assets	$55.53M	$18.80M	$55.53M	$18.80M	$152.62M	$397.36M	$825.74M
Current Liabilities	$4.72M	$5.69M	$4.72M	$5.69M	$9.15M	$6.72M	$11.69M
Total Debt	$0.00	$16.00K	$0.00	$16.00K	$4.00K	$0.00	$428.00K
Total Liabilities	$104.02M	$114.81M	$104.02M	$114.81M	$273.63M	$6.72M	$12.12M
Retained Earnings	-$49.23M	-$97.38M	-$49.23M	-$97.38M	-$123.42M	-$150.65M	-$174.16M
Shareholders' Equity	-$48.48M	-$96.02M	-$48.48M	-$96.02M	-$121.01M	$390.64M	$813.61M
Working Capital	$50.82M	$13.02M	$50.82M	$13.02M	$143.34M	$390.35M	$813.05M

MANE Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.63M	-$13.32M	-$15.64M	-$19.01M	-$23.63M	-$21.17M	-$14.49M
Capital Expenditure	—	-$19.00K	—	—	-$5.00K	—	—
Free Cash Flow	-$3.63M	-$13.34M	-$15.64M	-$19.01M	-$23.63M	-$21.17M	-$14.51M
Stock-Based Compensation	$91.00K	$213.00K	$115.00K	$138.00K	$974.00K	$5.26M	$3.52M
Investing Cash Flow	—	-$15.75M	-$8.33M	$15.00M	-$109.78M	-$101.30M	-$277.29M
Financing Cash Flow	$50.31M	$8.42M	$129.00K	$1.08M	$149.51M	$269.11M	$442.70M
Net Change in Cash	$46.67M	-$20.64M	-$23.84M	-$2.94M	$16.11M	$146.65M	$150.92M

Market Snapshot

About

Veradermics, Inc. is a dermatology therapeutics company focused on developing treatments for skin conditions. The company works on novel pharmaceutical solutions for dermatological disorders. Veradermics aims to address unmet needs in the dermatology market.